Dermatology · Santa Monica, CA
Dermatology and skin studies in Santa Monica, CA
7 recruiting studies have a site in Santa Monica.
7 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Santa Monica, CA + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Santa Monica, CA + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Pfizer
- Location
- Santa Monica, CA + 13 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Santa Monica, CA + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Novartis Pharmaceuticals
- Location
- Santa Monica, CA + 22 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Enveda Therapeutics
- Location
- Santa Monica, CA + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
UCB Biopharma SRL
- Location
- Santa Monica, CA + 5 other US sites
- Eligibility basics
- Ages 18+ · Women only
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.